Aggression · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Self‐injury · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
It is very uncertain whether neurohormones changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
Irritability · participants (any age) with a clinical diagnosis of ASD who have displayed one or more unwanted or challenging behaviours at baseline…
1 finding from 1 review
Clinical response at end of study (4 weeks) · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes clinical response at end of study (4 weeks) compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Clinical relapse · people with inflammatory bowel disease
Vitamin D (all doses) may leads to lower clinical relapse at end of study (26–52) weeks compared with placebo/no treatment (low certainty).
1 finding from 1 review
Quality of life at end of study (26 weeks) · people with inflammatory bowel disease
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Adverse events relating to treatment Scale: mild, moderate, severe and total · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Pulmonary exacerbations · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Nutrition and growth Change in: a) weight (kg) b) BMI (kg/m2) c) height (m) · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Sweat chloride level ‐ change from baseline Scale: mmol/L · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Mortality rate · adults and children with CF with at least one class I mutation (PTC)
1 finding from 1 review
Hypoglycaemia · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel leads to lower hypoglycaemia (investigator‐defined) compared with placebo (high certainty).
1 finding from 1 review
Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in major neurological disability at 2 years of age (Defined as any of… compared with placebo (low certainty).
1 finding from 1 review
Receipt of treatment for hypoglycaemia during initial hospital stay (investigator‐defined, any treatment ‐ oral dextrose gel, intravenous dextrose, or other drug therapy) during initial hospital stay (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of treatment for hypoglycaemia during initial hospital stay… compared with placebo (moderate certainty).
1 finding from 1 review
Receipt of intravenous treatment for hypoglycaemia (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of intravenous treatment for hypoglycaemia (yes/no) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events# (e.g. choking or vomiting at time of administration) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in adverse events# (e.g. choking or vomiting at time of administration) compared with placebo (moderate certainty).
1 finding from 1 review